Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension

Executive Summary

Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra

You may also be interested in...



FDA Endpoint Development For Pediatric Pulmonary Arterial Hypertension Focuses On Pfizer's Revatio

The standard exercise test is a problem for many pediatric patients, and FDA's Cardiovascular and Renal Drugs Advisory Committee will assess alternatives.

Lilly Brings Full Value Of Cialis In-House With Purchase Of Partner ICOS

Lilly will acquire its joint venture partner ICOS for approximately $2.1 bil. to gain the full rights to the erectile dysfunction drug Cialis (tadalafil), which the two companies have partnered on since 1998

Lilly Brings Full Value Of Cialis In-House With Purchase Of Partner ICOS

Lilly will acquire its joint venture partner ICOS for approximately $2.1 bil. to gain the full rights to the erectile dysfunction drug Cialis (tadalafil), which the two companies have partnered on since 1998

Related Content

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel